Jaguar is also supporting a third-party investigator evaluating crofelemer for eosinophilic colitis, another rare pediatric gastrointestinal condition
Proof-of-concept data for the use of crofelemer for pediatric orphan or rare disorders is expected to provide additional support for the potential for expanded patient access to crofelemer through programs in Europe in late 2023
SAN FRANCISCO, CA / ACCESSWIRE / December 19, 2022 / Jaguar…